When, if at all, is it appropriate to re-challenge a patient with a EGFR inhibitor in metastatic RAS/BRAF WT colon cancer?  

Would sidedness matter? Do you use ctDNA assays to evaluate for acquired RAS mutations to guide this decision?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at NYU Long Island School of Medicine
I agree with this approach. It is important to rev...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution